Jeffrey Eisenberg is the CEO of Xenetic Biosciences, a biotechnology company focused on cell-based therapeutics for B-cell lymphomas.
Jeffrey Eisenberg is the CEO of Xenetic Biosciences, a biotechnology company focused on cell-based therapeutics for B-cell lymphomas. He has presented the company's pre-clinical progress and plans for a Phase 1 trial. Under his leadership, Xenetic Biosciences has showcased data demonstrating DNase I's ability to enhance CAR-T cell persistence and tumor control.
Full founder directory · Investor directory · Company funding database · Fundraising library